APA

O'Brien S., Patel M., Kahl B. S., Horwitz S. M., Foss F. M., Porcu P., Jones J., Burger J., Jain N., Allen K., Faia K., Douglas M., Stern H. M., Sweeney J., Kelly P., Kelly V. & Flinn I. (20190819). Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. : American journal of hematology.

Chicago

O'Brien Susan, Patel Manish, Kahl Brad S, Horwitz Steven M, Foss Francine M, Porcu Pierluigi, Jones Jeffrey, Burger Jan, Jain Nitin, Allen Kerstin, Faia Kerrie, Douglas Mark, Stern Howard M, Sweeney Jennifer, Kelly Patrick, Kelly Virginia and Flinn Ian. 20190819. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. : American journal of hematology.

Harvard

O'Brien S., Patel M., Kahl B. S., Horwitz S. M., Foss F. M., Porcu P., Jones J., Burger J., Jain N., Allen K., Faia K., Douglas M., Stern H. M., Sweeney J., Kelly P., Kelly V. and Flinn I. (20190819). Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. : American journal of hematology.

MLA

O'Brien Susan, Patel Manish, Kahl Brad S, Horwitz Steven M, Foss Francine M, Porcu Pierluigi, Jones Jeffrey, Burger Jan, Jain Nitin, Allen Kerstin, Faia Kerrie, Douglas Mark, Stern Howard M, Sweeney Jennifer, Kelly Patrick, Kelly Virginia and Flinn Ian. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. : American journal of hematology. 20190819.